Stock page
Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Quote snapshot
$61.25
Daily change: —
ExchangeNAS
Updated2026-05-09T04:14:36.170661Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|